Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis
Joan Perelló(Sanifit (Spain)), Carolina Salcedo(Sanifit (Spain)), Bernat Isern(Sanifit (Spain)), Miguel D. Ferrer(Universidad de Zaragoza), Geert J. Behets(University of Antwerp), Vincent M. Brandenburg(Klinikum Rheine), Nadine Kaesler(RWTH Aachen University), María del Mar Pérez Gómez(Universidad de Granada), Patrick C. D’Haese(University of Antwerp), Rekha Garg(Therapeutics Clinical Research), Alex Gold(Portola Pharmaceuticals (United States)), Myles Wolf(Duke University)
Cited by 48
Related Papers
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
|The Lancet|2010|1.5k
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
|New England Journal of Medicine|2015|1k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Vitamin D levels and early mortality among incident hemodialysis patients
|Kidney International|2007|791
Activated Injectable Vitamin D and Hemodialysis Survival
|Journal of the American Society of Nephrology|2005|784